Nothing Special   »   [go: up one dir, main page]

CN101307015B - Process for preparing cilastatin sodium - Google Patents

Process for preparing cilastatin sodium Download PDF

Info

Publication number
CN101307015B
CN101307015B CN 200710099332 CN200710099332A CN101307015B CN 101307015 B CN101307015 B CN 101307015B CN 200710099332 CN200710099332 CN 200710099332 CN 200710099332 A CN200710099332 A CN 200710099332A CN 101307015 B CN101307015 B CN 101307015B
Authority
CN
China
Prior art keywords
formula
compound
dimethyl
heptenoic acid
cilastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN 200710099332
Other languages
Chinese (zh)
Other versions
CN101307015A (en
Inventor
卢兆强
张恒利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHENZHEN HAIBIN PHARMACEUTICAL CO Ltd
Original Assignee
SHENZHEN HAIBIN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHENZHEN HAIBIN PHARMACEUTICAL CO Ltd filed Critical SHENZHEN HAIBIN PHARMACEUTICAL CO Ltd
Priority to CN 200710099332 priority Critical patent/CN101307015B/en
Priority to PCT/CN2008/000947 priority patent/WO2008138228A1/en
Publication of CN101307015A publication Critical patent/CN101307015A/en
Application granted granted Critical
Publication of CN101307015B publication Critical patent/CN101307015B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26Separation; Purification; Stabilisation; Use of additives
    • C07C319/28Separation; Purification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a method for preparing a compound called cilastatin sodium shown as a formula (I). Cilastatin is prepared by crystallizing and purifying (Z)-7-chlorine-2((S)-2, 2-dimethyl c-pr carbamoyl)-2-heptenoic acid and the cilastatin sodium is prepared by purifying the cilastatin through microporous resin, thereby improving the purity quotient and the yield coefficient of the cilastatin sodium.

Description

A kind of method for preparing cilastatin sodium
Technical field
The present invention relates to a kind of preparation method of compound, relate in particular to a kind of method for preparing cilastatin sodium (Cilastain Sodium Salt).
Background technology
The chemistry of cilastatin sodium is called [R-[R *, S *(Z)] [(2-amino-2-carboxy ethyl) sulphur]-2-[[(2,2-dimethyl-cyclopropyl) carbonyl] amino]-2-heptenoic acid sodium]-7, its chemical structure is suc as formula (I), and molecular formula is C 12H 25N 2NaO 5S, molecular weight are 380.44.Cilastatin sodium and β-carbapenem antibiotic such as imipenum (imipenem) compatibility uses, and can suppress the degraded of kidney dehydrogenation pepx to imipenum, increases the concentration in ampere south, the urinary tract Central Asia, thereby improves the activity of imipenum, reduces its renal toxicity.Imipenum/cilastatin sodium is widely used as a kind of broad spectrum antimicrobicide.
Figure S07199332X20070601D000011
Existing at present a lot of reports about the cilastatin sodium preparation method.EP48301B1 begins to prepare cilastatin sodium after disclosing employing 1-bromo-5-chloropentane and Grignard reagent (Grignard Rx) reaction generation 7-chloro-2-oxoheptanoate; Donald W.Graham etc. discloses with 1,3-two thiophenes-2-ethyl formate as initial reactant prepare cilastatin sodium (Donald W.Graham etc., J.Med.Chem, 1987,30:1074), reactions step is following:
Figure S07199332X20070601D000021
Through 7-chloro-2-oxoheptanoate (III) with (S)-2,2-diformazan basic ring propyl formamide prepared in reaction gets formula (IV) compound (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid ethyl ester.
Because in step 2 preparation formula (IV) compound (Z)-7-chloro-2 ((S)-2; 2-dimethyl-cyclopropyl carboxamide base)-reaction of 2-heptenoic acid ethyl ester in; A small amount of (about 10%~13%) E formula isomer (E)-7-chloro-2 ((S)-2 are arranged; 2-dimethyl-cyclopropyl carboxamide base)-and 2-heptene ethyl ester (VII) generation, E formula isomer can further degraded production (VIII) compound (E)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid in the reaction of step 3.
Figure S07199332X20070601D000031
In order to overcome the problems referred to above; Attempt to add halfcystine reaction production (IX) compound (E)-7-(L-amino-2-propyloic) sulphur-2-((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid through acidizing crystal or in above-mentioned steps 3 gained reaction solns, acidifying heating isomery is removed impurity then; But find formula V compound (Z)-7-chloro-2 ((S)-2; 2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid crystallization yield is still very low, because in the reaction of step 3, generated by product (E)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (VIII); The acidifying of step 4 heating further causes not clear impurity (XI) and (S)-2; 2-dimethyl-cyclopropyl carboxamide (XII) generates, and makes the isolating difficulty of purification increase, and reaction process is following:
Figure S07199332X20070601D000032
Figure S07199332X20070601D000041
In order to address this problem; The PCT/WO2006/022511A1 application discloses following method: hydrolyzing type under alkaline condition (IV) compound (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid ethyl ester transfers to neutrality with reacting solution pH value; Then it is used the organic solvent crystallization; Prepare formula (XIII) compound (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid metal-salt, thereby removed formula V compound 7-chloro-2 ((S)-2; 2-dimethyl-cyclopropyl carboxamide base)-and the E formula isomer of 2-heptenoic acid, stoped next step reaction to generate the E formula isomer impurities of cilastatin (VI); Then with formula (XIII) compound (Z)-7-chloro-2 ((S)-2; 2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid metal-salt and halfcystine reaction; Through cationic exchange resin adsorption, the ammoniacal liquor elution, concentrate the back add alcohol refining formula (XIV) compound cilastatin ammonium; The sodium hydroxide solution of cilastatin ammonium (XIV) base exchange through Zeo-karb is prepared cilastatin sodium (I), and its reactions step is following:
But in the aforesaid method of PCT/WO2006/022511A1, because in carrying out the alkali swap operation process of Zeo-karb, the acid-base reaction liberated heat can cause that cilastatin (VI) decomposes on a small quantity and reduces the yield and the purity of product; In addition, loaded down with trivial details through the process operation of cilastatin ammonium (XIV) preparation cilastatin sodium (I), do not reach economic requirement, so still be not the method that a good industrialized is produced cilastatin sodium (I).
Summary of the invention
Therefore in order to remedy the deficiency of prior art, make the preparation of cilastatin sodium be fit to suitability for industrialized production, the invention provides a kind of novel method for preparing cilastatin sodium.
The present invention realizes through following technical scheme:
A kind of preparation chemical structural formula is (I), and chemical name is [R-[R *, S *(Z)] method of [(2-amino-2-carboxy ethyl) sulphur]-2-[[(2,2-dimethyl-cyclopropyl) carbonyl] amino]-2-heptenoic acid sodium]-7 comprises following step:
The crystallisate of 1) preparation formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl formyl radical)-2-heptenoic acid;
2) with crystallisate and the halfcystine or cysteine hydrochloride prepared in reaction formula (VI) the compound cilastatin of formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl formyl radical)-2-heptenoic acid;
3) with step 2) formula (VI) the compound cilastatin of preparation is through neutral purification with macroreticular resin;
4) with the formula behind the purifying (VI) compound cilastatin and alkaline sodium salt solution reaction, preparation cilastatin sodium (I) solid;
Figure S07199332X20070601D000061
Wherein X is a halogen atom.
Wherein the preparation method of the crystallisate of the described formula of step 1) (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl formyl radical)-2-heptenoic acid comprises:
A) with 7-X-2-oxoheptanoate and (+)-(S)-2,2-dimethyl-cyclopropane carboxamide prepared in reaction formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid;
B) prepare step a) to such an extent that formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl formyl radical)-2-heptenoic acid crystallization in methylene dichloride and toluene obtains the crystallisate of formula (XV) compound;
Wherein X is a chlorine or bromine.
Wherein the preparation method of the crystallisate of the described formula of step 1) (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl formyl radical)-2-heptenoic acid comprises:
A1) with 7-X-2-oxoheptanoate and (+)-(S)-2,2-dimethyl-cyclopropane carboxamide prepared in reaction formula (XV) compound (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid;
B1) prepare step a) to such an extent that formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl formyl radical)-2-heptenoic acid crystallization in dioxane and hexanaphthene obtains the crystallisate of formula (XV) compound;
Wherein X is a chlorine or bromine.
Wherein said neutral macroporous adsorbent resin is the HP-10 resin column, and elutriant is the mixing solutions of water, first alcohol and water.
The methyl alcohol in wherein said methyl alcohol and the water mixed solution and the weight ratio of water are 1:9.
Wherein the described alkaline sodium salt of step 4) is a sodium hydroxide.
Aforesaid method is prepared into highly purified formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid through crystallization, can effectively stop the E formula isomer of formula (VI) cilastatin to generate; Cilastatin solution is purified through neutral macroporous resin, reduced thermolysis and generated other impurity, thereby improved the purity and the yield of cilastatin sodium (I).
Embodiment
Further describe the present invention through the following example, make the present invention more clear be more readily understood.
The preparation of step 1 (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV)
(Z)-7-chloro-2 ((S)-2; 2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV) according to the EP48301B1 reported method with 247.8g7-chloro-2-oxoheptanoate (III); 135.6g (+)-S-2,2-dimethyl-cyclopropane carboxamide and 1.6g tosic acid are synthetic in 1200mL toluene, concentrate to reclaim toluene; Get the 359.3g brown viscous liquid, product is not done to separate and directly is used for next step reaction.
Last single step reaction gained 359.3g brown viscous liquid is added in the sodium hydroxide solution of 600mL ethanol and 720g10%, be heated to 45~50 ℃, insulated and stirred makes its reaction, and HPLC monitors reaction process, and reaction in about 10 hours finishes; Add tertbutyl ether washing reaction liquid then three times, add tertbutyl ether 1000mL at every turn, discard organic layer; Enriching hcl acidifying in water layer is regulated pH to 3~3.5, adds the ethyl acetate extraction acidizing fluid three times; Each amount that adds ETHYLE ACETATE is 1000mL, abandons water-yielding stratum, adds anhydrous sodium sulfate drying to ethyl acetate layer; Filter then, concentrating under reduced pressure filtrating is also reclaimed ETHYLE ACETATE, obtains 312.2 brown viscous liquids.
The preparation of step 2 (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid solid (IV) can have following two kinds of methods:
Under method one room temperature with 200g (Z)-7-chloro-2 ((S)-2; 2-dimethyl-cyclopropyl carboxamide base)-brown viscous liquid of 2-heptenoic acid (IV) is dissolved in the 500mL methylene dichloride, adds 1350mL toluene then, after stirring with gained solution place 0 ℃ static 12 hours; Collect a large amount of solids of separating out in the solution; Vacuum-drying gets white (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV) solid 98.5g.Be evaporated to constant weight with getting mother liquor after the crystallization simultaneously, get the brown viscous solution of 85g, according to aforesaid method; At room temperature the brown viscous solution of 85g is added 200mL methylene dichloride and 500mL toluene; 0 ℃ was descended freezing 12 hours, collected the solid of separating out in the solution, vacuum-drying; Obtain white (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV) solid 19.2g.Front and back obtain (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV) solid 117.7g twice altogether, and it is 98.7% that HPLC measures its purity, and yield is 56%.
Method two refluxes and down 200g is contained (Z)-7-chloro-2 ((S)-2; 2-dimethyl-cyclopropyl carboxamide base)-the brown viscous liquid solution 600mL dioxane of 2-heptenoic acid (IV) in, add the 1260mL hexanaphthene then, after stirring gained solution placed and left standstill under the room temperature 12 hours; A large amount of solids that collection is separated out; Vacuum-drying gets white (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV) solid 123.5g; It is 98.7% that HPLC measures its purity, and yield is 59%.
The preparation of step 3 cilastatin (VI)
Under the ice bath, 164.3g white (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV) solids are added in the sodium hydroxide solution of 1200g10%; Controlled temperature is less than or equal to 10 ℃; Stir and also to feed nitrogen, treat that (Z)-7-chloro-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid (IV) solid is all after the dissolving; Add 105.3g cysteine hydrochloride monohydrate, controlled temperature is less than or equal to 10 ℃ simultaneously; After adding, in about 5 ℃, continue to stir 0.5 hour, be warming up to 55~60 ℃ then, insulated and stirred makes its reaction, HPLC monitoring reaction process, and reaction in about 8 hours finishes; After question response finishes, will react liquid cooling and go to room temperature, and add washed with dichloromethane 3 times, add methylene dichloride is 600mL at every turn, discards organic layer, adds the long-pending water of reaction solution monoploid, adds strong brine regulator solution pH value to 2.5~3.0 then; In solution, add the washed with dichloromethane reaction solution 4 times after the acidifying, each methylene dichloride that adds is 800mL, discards organic layer; 55 ℃ are evaporated to the half the of liquor capacity to original volume, and gained solution is added the HP-10 resin column, use earlier water elution; After the sodium-chlor wash-out that generates in the question response finishes, use the methanol/water solution wash-out of 10/90 (wt/wt) again, collect the cilastatin solution of gained; 55 ℃ are concentrated into driedly, and vacuum-drying is to constant weight, light yellow cilastatin solid (VI) 127.8g; It is 98.5% that HPLC measures its purity, and yield is 59.5%.
The preparation of step 4 cilastatin sodium (I)
150g cilastatin (VI) solid that step 3 is prepared adds in the 500mL water, stirs, and sodium hydroxide to the pH value that under ice bath, slowly is added dropwise to 2.08mol/L (16.6g sodium hydroxide is dissolved in the 200mL water) is 7.0; Stop the dropping of sodium hydroxide solution, continue to stir 0.5 hour, treat pH value of solution value and temperature-stable after; In solution, add the 3.5g activated carbon; 40 ℃ are stirred decolouring 15 minutes down, with 0.45 μ m millipore filtration suction filtration, with gained filtrating warp 0.20 μ m filter core press filtration to sterilisable chamber; Collect filtrating with the filtrating refrigerator tray of packing into; Lyophilize gets white aseptic cilastatin sodium (I) lyophilized powder 143.3g, and it is 98.8% that HPLC measures its purity, and yield is 90%.
Above embodiment does not all limit the present invention going up in all senses, if of the present invention these are revised with modification belongs within the scope of claim of the present invention and equivalent technologies thereof, and then the present invention also is intended to comprise these changes and modification interior.

Claims (3)

1. one kind prepares chemical structural formula for (I), and chemical name is the method for [R-[R*, S* (Z)]]-7 [(2-amino-2-carboxy ethyl) sulphur]-2-[[(2,2-dimethyl-cyclopropyl) carbonyl] amino]-2-heptenoic acid sodium, comprises following step:
The crystallisate of 1) preparation formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid;
2) with crystallisate and the halfcystine or cysteine hydrochloride prepared in reaction formula (VI) the compound cilastatin of formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid;
3) with step 2) formula (VI) the compound cilastatin of preparation is through HP-10 resin column purifying, and elutriant is the mixing solutions of water, first alcohol and water;
4) with the formula behind the purifying (VI) compound cilastatin and alkaline sodium salt solution reaction, preparation formula (I) compound cilastatin sodium solid;
Figure FSB00000398807000011
Figure FSB00000398807000021
Wherein X is a halogen atom,
Wherein the preparation method of the crystallisate of the described formula of step 1) (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid comprises:
A) with 7-X-2-oxoheptanoate and (+)-(S)-2, the reaction of 2-dimethyl-cyclopropane carboxamide obtains brown viscous liquid, does not do to separate in the sodium hydroxide solution of direct adding ethanol and 10%, is heated to 45~50 ℃; Insulated and stirred reaction 10 hours adds the tertbutyl ether washing then, discards organic layer; Enriching hcl acidifying in water layer is regulated pH to 3~3.5, adds ethyl acetate extraction; Discard water layer, ethyl acetate layer is dry, filters; Concentrating under reduced pressure, preparation formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid;
B) step a) is prepared formula (XV) compound (Z)-7-X-2 ((S)-2,2-dimethyl-cyclopropyl carboxamide base)-2-heptenoic acid crystallization in methylene dichloride and toluene or in dioxane and hexanaphthene and obtain the crystallisate of formula (XV) compound.
2. the method for claim 1, the methyl alcohol in wherein said methyl alcohol and the water mixed solution and the weight ratio of water are 1: 9.
3. the method for claim 1, wherein the described alkaline sodium salt of step 4) is a sodium hydroxide.
CN 200710099332 2007-05-16 2007-05-16 Process for preparing cilastatin sodium Active CN101307015B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN 200710099332 CN101307015B (en) 2007-05-16 2007-05-16 Process for preparing cilastatin sodium
PCT/CN2008/000947 WO2008138228A1 (en) 2007-05-16 2008-05-15 A process for the preparation of cilastatin sodium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200710099332 CN101307015B (en) 2007-05-16 2007-05-16 Process for preparing cilastatin sodium

Publications (2)

Publication Number Publication Date
CN101307015A CN101307015A (en) 2008-11-19
CN101307015B true CN101307015B (en) 2012-06-13

Family

ID=40001686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200710099332 Active CN101307015B (en) 2007-05-16 2007-05-16 Process for preparing cilastatin sodium

Country Status (2)

Country Link
CN (1) CN101307015B (en)
WO (1) WO2008138228A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675175B (en) * 2011-03-08 2014-02-19 深圳市海滨制药有限公司 Method for separating and purifying cilastatin
CN102702051B (en) * 2011-03-26 2016-04-13 山东新时代药业有限公司 A kind of preparation method of cilastatin sodium
CN104649948B (en) * 2013-11-19 2017-05-24 江苏迪赛诺制药有限公司 Cilastatin calcium crystal, preparation method and application thereof
CN106518741B (en) * 2016-10-21 2018-11-16 深圳市海滨制药有限公司 A kind of preparation method of Cilastatin Sodium bulk pharmaceutical chemicals
CN107522642A (en) * 2017-08-14 2017-12-29 新乡海滨药业有限公司 A kind of process for purification of cilastatin
CN110305033B (en) * 2018-03-20 2020-08-28 鲁南制药集团股份有限公司 Purification method of cilastatin sodium intermediate
CN110845354B (en) * 2018-08-21 2020-08-25 鲁南制药集团股份有限公司 Preparation method of cilastatin sodium intermediate
CN109111381A (en) * 2018-10-30 2019-01-01 雅本化学股份有限公司 A kind of preparation method of cilastatin
CN115108934B (en) * 2022-07-08 2024-02-06 珠海联邦制药股份有限公司 Preparation method of cilastatin intermediate sodium
CN115260067A (en) * 2022-08-26 2022-11-01 同舟纵横(厦门)流体技术有限公司 Method for purifying cilastatin mother liquor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1592737A (en) * 2001-08-24 2005-03-09 兰贝克赛实验室有限公司 Process for the preparation of cilastatin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE48301T1 (en) * 1980-09-24 1983-01-20 Merck & Co., Inc., 07065 Rahway, N.J. 2- (CYCLOPROPANCARBOXAMIDO) -2-ALKO ACIDS, THEIR ESTERS AND SALTS AND THE EXISTING BACTERIAL INHIBITING COMPOSITIONS WITH A TYPE THIENAMYCINE COMPOUND.
KR100638471B1 (en) * 2004-08-25 2006-10-25 동국제약 주식회사 Novel Process for Preparing Cilastatin Sodium Salt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1592737A (en) * 2001-08-24 2005-03-09 兰贝克赛实验室有限公司 Process for the preparation of cilastatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈扬.西司他丁钠及其E构型异构体的合成.《陈扬学位论文》.2007,22,29-32. *

Also Published As

Publication number Publication date
WO2008138228A1 (en) 2008-11-20
CN101307015A (en) 2008-11-19

Similar Documents

Publication Publication Date Title
CN101307015B (en) Process for preparing cilastatin sodium
CN103450225B (en) The preparation method of cefoxitin sodium
CN102775364A (en) Preparation method of cross linking agent triallyl isocyanurate
CN101619069A (en) Preparation method of cefotiam hexetil hydrochloride
CN103360410B (en) Ofloxacine USP 23 preparation method
CN111004162B (en) A kind of method and device for preparing L-selenocystine with sodium triacetoxyborohydride as reducing agent
CN109096129B (en) Preparation method of L-carnitine tartrate
CN1679586A (en) Novel synthesis and crystallization of piperazine ring-containing compounds
CN109836424B (en) Method for preparing caffeine by methylation of environment-friendly theophylline sodium salt
CN115991655B (en) Synthesis method and product of m-hydroxylamine bitartrate and key intermediate enantiomer thereof
CN106279207A (en) A kind of synthetic method of cefdinir
CN117304049A (en) Preparation method of N,2, 3-trimethyl-2-isopropyl butyramide cooling agent
CN101612551B (en) Preparation of medical sodium benzoate
CN105017287B (en) A kind of preparation method of cephamycin intermediate
CN109912625B (en) Process method for reducing ceftazidime impurity H
CN110229111B (en) Ambroxol impurity and preparation method and application thereof
CN102702051A (en) Preparation method of cilastatin sodium
CN100398507C (en) DL-amygdalic acid preparing method
CN100383114C (en) Nateglinide preparing process
CN114315703B (en) Preparation method of high-purity vitamin B6
CN104710437A (en) Improved method for preparing d-biotin from bisbenzyl biotin by debenzylation
CN112679361B (en) Synthetic method of 3-fluoro-5-nitropyridine-2-formaldehyde
CN109053797A (en) A kind of improvement synthetic method of oxygen phosphoric acid-l-tyrosine
CN108484669B (en) Preparation method of thiotepa
CN102675175A (en) Method for separating and purifying cilastatin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant